Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

Abroad (travel likely)RecruitingPHASE2

Conditions

Light Chain (AL) Amyloidosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Kaini Shen, MD) · shenkaini3@sina.com · 86+13693339884

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Amyloidosis

Abroad (travel likely)RecruitingPHASE2

Rochester, United States · Westmead, Australia

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Relapsed AL Amyloidosis · Refractory AL Amyloidosis · Light Chain Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · San Francisco, United States

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Immunoglobulin Light Chain (AL) Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Miami, United States · Boston, United States

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis · Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Nashville, United States · Dallas, United States